Table 4.
Absorbed dose (mGy) and effective dose (mSv) per injected activity (MBq) for [43/44/44mSc]Sc-DOTATATE, [68Ga]Ga-DOTATATE, and [111In]In-Octreotide
| Phantom | Organs | DOTATATE | [lnIn]In-Oetreotidc [21] | |||
|---|---|---|---|---|---|---|
| Scandium-43 | Scandium-44 | Scandium-44m | Gallium-68 | |||
| AF | Kidneys | 8.9E−2 ± 2.9E−4 | 1.4E−1 ± 3.4E−4 | 1.6E−1 ± 8.0E−4 | 4.0E−2 ± 9.4E−5 | 4.1E−1 |
| AM | 7.8E−2 ± 8.6E−5 | 1.2E−1 ± 1.3E−4 | 1.5E−1 ± 2.5E−4 | 3.5E−2 ± 7.7E−5 | ||
| Liver | 9.0E−2 ± 6.2E−5 | 1.4E−1 ± 8.4E−5 | 1.8E−1 ± 2.0E−5 | 4.0E−2 ± 2.2E−5 | 1.0E−1 | |
| 7.2E−2 ± 2.9E−5 | 1.2E−1 ± 4.4E−5 | 1.5E−1 ± 9.3E−5 | 3.1E−2 ± 1.7E−5 | |||
| RBM | 5.6E−3 ± 2.9E−5 | 1.0E−2 ± 5.0E−5 | 1.8E−2 ± 1.3E−5 | 2.0E−3 ± 8.2E−6 | 2.0E−2 | |
| 4.4E−3 ± 5.8E−6 | 8.3E−3 ± 1.2E−5 | 1.5E−2 ± 3.2E−5 | 1.5E−3 ± 5.5E−6 | |||
| Spleen | 1.3E−1 ± 2.8E−4 | 2.0E−1 ± 3.5E−4 | 2.2E−1 ± 7.0E−4 | 6.0E−2 ± 1.0E−4 | 5.7E−1 | |
| 1.2E−1 ± 1.4E−4 | 1.8E−1 ± 2.1E−4 | 2.0E−1 ± 3.3E−4 | 5.3E−2 ± 8.5E−5 | |||
| Effective dose (mSv/MBq) | 1.1E−2 ± 5.7E−6 | 2.0E−2 ± 9.6E−5 | 2.9E−2 ± 2.5E−5 | 4.5E−3 ± l.GE−5 | 5.4E−2 | |
| 9.2E−3 ± 1.2E−5 | 1.6E−2 ± 2.5E−5 | 2.5E−2 ± 6.8E−5 | 3.6E−3 ± 1.4E−5 | |||